Wnt/β-catenin activation by mutually exclusive FBXW11 and CTNNB1 hotspot mutations drives salivary basal cell adenoma.
Saved in:
| Title: | Wnt/β-catenin activation by mutually exclusive FBXW11 and CTNNB1 hotspot mutations drives salivary basal cell adenoma. |
|---|---|
| Authors: | Wong K; Experimental Cancer Genetics, Wellcome Sanger Institute, Hinxton, Cambridge, UK., Bishop JA; Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas, USA., Weinreb I; Laboratory Medicine Program, University Health Network, Toronto General Hospital, Toronto, ON, Canada.; Department of Pathobiology and Laboratory Medicine, University of Toronto, Toronto, ON, Canada., Motta M; Molecular Genetics and Functional Genomics, Ospedale Pediatrico Bambino Gesù, IRCCS, Rome, Italy., Del Castillo Velasco-Herrera M; Experimental Cancer Genetics, Wellcome Sanger Institute, Hinxton, Cambridge, UK., Bellacchio E; Molecular Genetics and Functional Genomics, Ospedale Pediatrico Bambino Gesù, IRCCS, Rome, Italy., Ferreira I; Experimental Cancer Genetics, Wellcome Sanger Institute, Hinxton, Cambridge, UK., van der Weyden L; Experimental Cancer Genetics, Wellcome Sanger Institute, Hinxton, Cambridge, UK., Boccacino JM; Experimental Cancer Genetics, Wellcome Sanger Institute, Hinxton, Cambridge, UK., Lauri A; Molecular Genetics and Functional Genomics, Ospedale Pediatrico Bambino Gesù, IRCCS, Rome, Italy., Rotundo G; Molecular Genetics and Functional Genomics, Ospedale Pediatrico Bambino Gesù, IRCCS, Rome, Italy., Ciolfi A; Molecular Genetics and Functional Genomics, Ospedale Pediatrico Bambino Gesù, IRCCS, Rome, Italy., Cheema S; Experimental Cancer Genetics, Wellcome Sanger Institute, Hinxton, Cambridge, UK., Olvera-León R; Experimental Cancer Genetics, Wellcome Sanger Institute, Hinxton, Cambridge, UK., Offord V; Experimental Cancer Genetics, Wellcome Sanger Institute, Hinxton, Cambridge, UK., Droop A; Experimental Cancer Genetics, Wellcome Sanger Institute, Hinxton, Cambridge, UK., Vermes I; Experimental Cancer Genetics, Wellcome Sanger Institute, Hinxton, Cambridge, UK., Allgäuer M; Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany., Hyrcza M; Department of Pathology and Laboratory Medicine, University of Calgary, Arnie Charboneau Cancer Institute, Calgary, AB, Canada., Anderson E; Experimental Cancer Genetics, Wellcome Sanger Institute, Hinxton, Cambridge, UK., Smith K; Experimental Cancer Genetics, Wellcome Sanger Institute, Hinxton, Cambridge, UK., de Saint Aubain N; Department of Pathology, Hôpital Universitaire de Bruxelles (HUB), Université Libre de Bruxelles, Brussels, Belgium., Mogler C; School of Medicine and Health, Technical University Munich, Munich, Germany., Stenzinger A; Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany., Arends MJ; Edinburgh Pathology, Cancer Research UK Scotland Centre, The University of Edinburgh, Institute of Genetics and Cancer, Edinburgh, UK., Brenn T; Departments of Pathology and Dermatology, University of Michigan, Ann Arbor, Michigan, USA., Tartaglia M; Molecular Genetics and Functional Genomics, Ospedale Pediatrico Bambino Gesù, IRCCS, Rome, Italy., Adams DJ; Experimental Cancer Genetics, Wellcome Sanger Institute, Hinxton, Cambridge, UK. da1@sanger.ac.uk. |
| Source: | Nature communications [Nat Commun] 2025 May 19; Vol. 16 (1), pp. 4657. Date of Electronic Publication: 2025 May 19. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2041-1723 |
|---|---|
| DOI: | 10.1038/s41467-025-59871-3 |
